Clariant is to invest CHF 80 million to expand its Care Chemicals facility at Daya Bay in Huizhou, China, by the end of 2024. This will both add capacity for existing products and introduce new products in the pharmaceutical, personal care, home care and industrial sector.

Daya Bay, which has obtained the drug GMP certificate, is the first API site in China certified to produce polyethylene glycol Polyglykol 3350. More generally, it will become new global hub for Clariant’s healthcare business support.

Dow has announced what it described as “a series of incremental, high-return capacity expansions to support growing demand across key end-markets, all of which value sustainable solutions and continue to grow faster than GDP”. Most relate in full or in part to specialities.